Non-Small-Cell Lung Cancer – Epidemiology – Mature Markets

Clarivate Epidemiology's coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of NSCLC for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the major mature pharmaceutical markets.

Clarivate Epidemiology's NSCLC forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with NSCLC per year?
  • In developing countries, what impact will economic growth and development have on the number of first-line drug-treatment opportunities for NSCLC?
  • How will improvements in survival change the number of people living with NSCLC?
  • Of all people diagnosed with NSCLC, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NSCLC over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

In total, Clarivate Epidemiology forecasts over 100 NSCLC patient populations, including the following:

  • Diagnosed incident cases of NSCLC by stage.
  • Diagnosed incident cases of NSCLC by histology.
  • Diagnosed metastatic recurrent incident cases of NSCLC by histology.
  • Diagnosed prevalent cases of NSCLC by histology.
  • Diagnosed first-line NSCLC metastatic drug-treatable population.
  • Diagnosed NSCLC drug-treated population.

Note: coverage may vary by country.

Table of contents

  • Non-Small-Cell Lung Cancer - Epidemiology - Mature Markets
    • Epidemiology data
    • Methods
      • Literature review (studies included in/excluded from the analyses of non-small-cell lung cancer)
      • Diagnosed incident cases
      • Stage distribution
      • ALK mutation
      • EGFR mutation
      • KRAS mutation
      • Recurrent incident cases
      • Diagnosed prevalent cases
      • Drug-treatable populations
      • Drug-treated populations
      • Risk / protective factors applied to disease forecast models
    • Reference materials
      • Bibliography
      • Glossary
      • Abbreviation table

Login to access report

launch Related Market Assessment Reports